Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.51
NYSE:Q's Cash to Debt is ranked lower than
73% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. NYSE:Q: 0.51 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:Q' s Cash to Debt Range Over the Past 10 Years
Min: 0.19  Med: 0.38 Max: N/A
Current: 0.51
Equity to Asset -0.08
NYSE:Q's Equity to Asset is ranked lower than
93% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NYSE:Q: -0.08 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:Q' s Equity to Asset Range Over the Past 10 Years
Min: -0.55  Med: -0.2 Max: -0.08
Current: -0.08
-0.55
-0.08
Interest Coverage 6.86
NYSE:Q's Interest Coverage is ranked lower than
78% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 83.10 vs. NYSE:Q: 6.86 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:Q' s Interest Coverage Range Over the Past 10 Years
Min: 2.79  Med: 3.46 Max: 6.86
Current: 6.86
2.79
6.86
F-Score: 6
Z-Score: 4.75
M-Score: -2.76
WACC vs ROIC
7.24%
40.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 11.14
NYSE:Q's Operating margin (%) is ranked higher than
74% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.98 vs. NYSE:Q: 11.14 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:Q' s Operating margin (%) Range Over the Past 10 Years
Min: 7.98  Med: 9.57 Max: 11.27
Current: 11.14
7.98
11.27
Net-margin (%) 6.55
NYSE:Q's Net-margin (%) is ranked higher than
69% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.37 vs. NYSE:Q: 6.55 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:Q' s Net-margin (%) Range Over the Past 10 Years
Min: 3.65  Med: 5.02 Max: 6.75
Current: 6.55
3.65
6.75
ROA (%) 9.91
NYSE:Q's ROA (%) is ranked higher than
86% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.94 vs. NYSE:Q: 9.91 )
Ranked among companies with meaningful ROA (%) only.
NYSE:Q' s ROA (%) Range Over the Past 10 Years
Min: 7.36  Med: 10.72 Max: 20.82
Current: 9.91
7.36
20.82
ROC (Joel Greenblatt) (%) 359.65
NYSE:Q's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.88 vs. NYSE:Q: 359.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:Q' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 211.6  Med: 309.22 Max: 359.65
Current: 359.65
211.6
359.65
Revenue Growth (3Y)(%) 3.40
NYSE:Q's Revenue Growth (3Y)(%) is ranked higher than
50% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. NYSE:Q: 3.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:Q' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 3.4  Med: 4.3 Max: 6.2
Current: 3.4
3.4
6.2
EBITDA Growth (3Y)(%) 13.00
NYSE:Q's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. NYSE:Q: 13.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:Q' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 2.4  Med: 13 Max: 19.1
Current: 13
2.4
19.1
EPS Growth (3Y)(%) 26.80
NYSE:Q's EPS Growth (3Y)(%) is ranked higher than
83% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.00 vs. NYSE:Q: 26.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:Q' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 9.2  Med: 9.9 Max: 26.8
Current: 26.8
9.2
26.8
» NYSE:Q's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

Q Guru Trades in Q4 2015

John Hussman 50,000 sh (New)
Paul Tudor Jones 28,686 sh (+133.22%)
Ken Fisher 54,173 sh (+12.21%)
Ron Baron 507,583 sh (+7.51%)
Vanguard Health Care Fund 4,774,398 sh (-9.82%)
Jim Simons 175,100 sh (-29.76%)
Joel Greenblatt 76,919 sh (-76.69%)
» More
Q1 2016

Q Guru Trades in Q1 2016

Columbia Wanger 1,375,000 sh (New)
Jim Simons 660,100 sh (+276.98%)
Joel Greenblatt 224,517 sh (+191.89%)
Ron Baron 516,806 sh (+1.82%)
John Hussman Sold Out
Ken Fisher 54,064 sh (-0.20%)
Paul Tudor Jones 23,076 sh (-19.56%)
Vanguard Health Care Fund 1,932,338 sh (-59.53%)
» More
Q2 2016

Q Guru Trades in Q2 2016

Larry Robbins 1,919,555 sh (New)
John Paulson 164,200 sh (New)
Ken Fisher 88,164 sh (+63.07%)
Paul Tudor Jones 37,446 sh (+62.27%)
Joel Greenblatt 350,600 sh (+56.16%)
Vanguard Health Care Fund 2,929,638 sh (+51.61%)
Jim Simons 528,700 sh (-19.91%)
Columbia Wanger 1,010,406 sh (-26.52%)
Ron Baron 371,210 sh (-28.17%)
» More
Q3 2016

Q Guru Trades in Q3 2016

Larry Robbins 3,381,622 sh (+76.17%)
Ken Fisher 126,587 sh (+43.58%)
John Paulson Sold Out
Vanguard Health Care Fund 2,539,738 sh (-13.31%)
Columbia Wanger 836,973 sh (-17.16%)
Ron Baron 300,810 sh (-18.97%)
Joel Greenblatt 241,654 sh (-31.07%)
Jim Simons 242,300 sh (-54.17%)
Paul Tudor Jones 16,149 sh (-56.87%)
» More
» Details

Insider Trades

Latest Guru Trades with Q

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NYSE:A, NYSE:LH, OTCPK:SSMXY, NYSE:DGX, NAS:IDXX, OTCPK:ERFSF, NAS:QGEN, NAS:DXCM, OTCPK:BMXMF, NYSE:PKI, NYSE:BIO.B, NAS:ICLR, NAS:CPHD, NAS:BRKR, NAS:VWR, NYSE:CRL, NYSE:ALR, NAS:PRAH, NAS:PRXL, NAS:INCR » details
Traded in other countries:QTS.Germany,
Quintiles Transnational Holdings Inc provides biopharmaceutical development services and commercial outsourcing services. Its two operating segments are Product Development segment and Integrated Healthcare Services segment.

Quintiles IMS Holdings Inc, formerly known as Quintiles Transnational Holdings Inc was founded in February 1982. The Company completed its initial public offering on May 9, 2013. It is an information and technology company. The Company offers professional services, information technology and partnering solutions to the pharmaceutical services, biotechnology and healthcare industries.

Ratios

vs
industry
vs
history
P/E(ttm) 23.87
Q's P/E(ttm) is ranked higher than
67% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.23 vs. Q: 23.87 )
Ranked among companies with meaningful P/E(ttm) only.
Q' s P/E(ttm) Range Over the Past 10 Years
Min: 18.67  Med: 23.76 Max: 31.48
Current: 23.87
18.67
31.48
Forward P/E 17.61
Q's Forward P/E is ranked higher than
70% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.19 vs. Q: 17.61 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 23.87
Q's PE(NRI) is ranked higher than
68% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.23 vs. Q: 23.87 )
Ranked among companies with meaningful PE(NRI) only.
Q' s PE(NRI) Range Over the Past 10 Years
Min: 18.67  Med: 23.76 Max: 31.48
Current: 23.87
18.67
31.48
Price/Owner Earnings (ttm) 20.43
Q's Price/Owner Earnings (ttm) is ranked higher than
70% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.10 vs. Q: 20.43 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
Q' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 15.82  Med: 19.42 Max: 21.33
Current: 20.43
15.82
21.33
P/S 1.56
Q's P/S is ranked higher than
75% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. Q: 1.56 )
Ranked among companies with meaningful P/S only.
Q' s P/S Range Over the Past 10 Years
Min: 1.02  Med: 1.4 Max: 1.77
Current: 1.56
1.02
1.77
PFCF 18.34
Q's PFCF is ranked higher than
65% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.06 vs. Q: 18.34 )
Ranked among companies with meaningful PFCF only.
Q' s PFCF Range Over the Past 10 Years
Min: 14.22  Med: 21.25 Max: 35.19
Current: 18.34
14.22
35.19
POCF 15.36
Q's POCF is ranked higher than
61% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.55 vs. Q: 15.36 )
Ranked among companies with meaningful POCF only.
Q' s POCF Range Over the Past 10 Years
Min: 12.28  Med: 16.87 Max: 26.51
Current: 15.36
12.28
26.51
EV-to-EBIT 30.55
Q's EV-to-EBIT is ranked lower than
65% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.61 vs. Q: 30.55 )
Ranked among companies with meaningful EV-to-EBIT only.
Q' s EV-to-EBIT Range Over the Past 10 Years
Min: 13.7  Med: 16.3 Max: 30.65
Current: 30.55
13.7
30.65
EV-to-EBITDA 25.56
Q's EV-to-EBITDA is ranked lower than
67% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.28 vs. Q: 25.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
Q' s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.5  Med: 13.5 Max: 25.64
Current: 25.56
11.5
25.64
PEG 2.10
Q's PEG is ranked higher than
65% of the 37 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. Q: 2.10 )
Ranked among companies with meaningful PEG only.
Q' s PEG Range Over the Past 10 Years
Min: 0  Med: 0 Max: 10013.4
Current: 2.1
0
10013.4
Current Ratio 1.63
Q's Current Ratio is ranked lower than
71% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. Q: 1.63 )
Ranked among companies with meaningful Current Ratio only.
Q' s Current Ratio Range Over the Past 10 Years
Min: 1.15  Med: 1.44 Max: 1.65
Current: 1.63
1.15
1.65
Quick Ratio 1.63
Q's Quick Ratio is ranked lower than
64% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. Q: 1.63 )
Ranked among companies with meaningful Quick Ratio only.
Q' s Quick Ratio Range Over the Past 10 Years
Min: 1.15  Med: 1.44 Max: 1.65
Current: 1.63
1.15
1.65
Days Sales Outstanding 33.26
Q's Days Sales Outstanding is ranked higher than
89% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.99 vs. Q: 33.26 )
Ranked among companies with meaningful Days Sales Outstanding only.
Q' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.13  Med: 29.27 Max: 35.22
Current: 33.26
25.13
35.22

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.40
Q's 3-Year Average Share Buyback Ratio is ranked higher than
75% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.50 vs. Q: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
Q' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.2  Med: -1.7 Max: -0.4
Current: -0.4
-3.2
-0.4

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.12
Q's Price/Median PS Value is ranked lower than
55% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. Q: 1.12 )
Ranked among companies with meaningful Price/Median PS Value only.
Q' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.73  Med: 0.98 Max: 1.19
Current: 1.12
0.73
1.19
Earnings Yield (Greenblatt) (%) 3.22
Q's Earnings Yield (Greenblatt) (%) is ranked higher than
69% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. Q: 3.22 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
Q' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.21  Med: 6.1 Max: 7.3
Current: 3.22
3.21
7.3

More Statistics

Revenue (TTM) (Mil) $6,062
EPS (TTM) $ 3.25
Beta0.71
Short Percentage of Float9.00%
52-Week Range $55.01 - 81.45
Shares Outstanding (Mil)246.18

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 5,359 8,319 8,813
EPS ($) 3.70 4.37 5.26
EPS w/o NRI ($) 3.70 4.37 5.26
EPS Growth Rate
(3Y to 5Y Estimate)
14.03%
Dividends Per Share ($)
» More Articles for NYSE:Q

Headlines

Articles On GuruFocus.com
The Big 3: Larry Robbins' Top 2nd-Quarter Buys Aug 16 2016 
Weekly 3-Year Low Highlight: TDC, Q, GRAM, XCO Dec 09 2013 
Vanguard Health Care Fund Gains 27%, Buys 4 New Stocks Jul 31 2013 
AT&T Inc. (T) Dividend Stock Analysis Jan 27 2011 
Stocks Jim Simons Keeps on Buying: CL, Q, LMT, NVO, HRB Jan 25 2011 
CenturyLink, Inc. – A Qwest for Growth Nov 22 2010 
Which S&P 500 Company Has the Shakiest Dividend: AT&T, Pepco, Qwest, CenturyTel, Diamond Offshore May 17 2010 

More From Other Websites
Drug spending around the world will hit $1.5 trillion by 2021 Dec 06 2016
QuintilesIMS Institute Forecast: Global Drug Market Will Reach Nearly $1.5 Trillion in 2021 as... Dec 06 2016
Global prescription drug spend seen at $1.5 trillion in 2021 - report Dec 06 2016
ETFs with exposure to Quintiles IMS Holdings, Inc. : December 2, 2016 Dec 02 2016
QuintilesIMS downgraded by BofA/Merrill Dec 02 2016
QuintilesIMS Named Best Full-service Provider CRO in 2016 Scrip Awards Dec 01 2016
Quintiles IMS Holdings, Inc. breached its 50 day moving average in a Bearish Manner : Q-US :... Dec 01 2016
Former CEO Tom Pike to leave QuintilesIMS Nov 30 2016
QUINTILES IMS HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Nov 30 2016
QuintilesIMS Announces Executive Leadership Changes Nov 30 2016
QuintilesIMS Forms New Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt,... Nov 22 2016
QuintilesIMS Forms New Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt,... Nov 22 2016
Corsair Capital Talks REIT Mega-Merger, Voya Financial (VOYA), Olin (OLN), More Nov 21 2016
QuintilesIMS to acquire clinical trials division of New Jersey firm Nov 21 2016
Post Earnings Coverage as PerkinElmer Q3 Bottomline Outperformed Estimates Nov 15 2016
Quintiles IMS Holdings, Inc. breached its 50 day moving average in a Bullish Manner : Q-US :... Nov 10 2016
QUINTILES IMS HOLDINGS, INC. Financials Nov 09 2016
3 Cheap Stocks With Shifting Moats Nov 09 2016
QuintilesIMS Chairman & CEO Ari Bousbib to Speak at J.P. Morgan Ultimate Services Conference on... Nov 08 2016
ETF’s with exposure to Quintiles IMS Holdings, Inc. : November 4, 2016 Nov 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)